Navigation Links
Nuvilex Launches Video Marketing Campaign
Date:6/1/2009

CHERRY HILL, N.J., June 1 /PRNewswire-FirstCall/ -- Nuvilex, Inc. (OTC Bulletin Board: NVLX), an emerging healthcare consumer products company is now airing the first in a series of videos to promote the company and its products. Chairman and CEO Martin Schmieg leads off with an overview of the company's innovative and diverse product lines. This video is now running on the Nuvilex website at www.nuvilex.com and will be featured in corporate presentations and the Company's business development efforts.

Next up is a video commercial to promote Nuvilex' Last Shot Hangover Remedy. This new product eases hangover symptoms and is expected to launch Q3 2009 (July) in North America and Q4 2009 (October) worldwide. The Last Shot Hangover Remedy will air on various platforms including television, movie previews, and the Internet. Miller + Partners has been engaged to produce Nuvilex' video campaign.

About Miller + Partners

For over two decades, the consulting team at MILLER+PARTNERS has helped hundreds of top companies leverage the screen to communicate better, build brand awareness and heighten the users experience. Our Powermercial(TM) products enable our clients to reach across the social and sharing networks with engaging, entertaining and market focused video. For more information about Miller + Partners please visit us at www.GreatVideoSells.com.

About Nuvilex, Inc.

Nuvilex, formerly eFoodSafety.com, is an emerging healthcare consumer products company with a portfolio of aesthetics, dermatology, environmental and nutraceutical products. The company's focus is on developing, licensing and commercializing healthcare products that address the health needs of consumers worldwide. In March 2009, Nuvilex merged with Freedom2 Holdings, Inc., a diversified skin products technology company serving the fast-growing body art, aesthetic, cosmetic and skin therapy markets. More information is available at: http://www.nuvilex.com or www.freedom2inc.com.

Safe Harbor Statement

Statements contained in this presentation that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Forward-looking statements are sometimes identified by words such as "intends", "anticipates", "believes", "expects", and "hopes" and involve a number of risks and uncertainties that could cause the Company's actual results to differ materially from projected results. All parties are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, the planned share exchange with Freedom2 Holdings, Inc., our ability to secure additional financing, and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

    Investor Relations Contacts:

    Blair Barnes
    Senior Vice President and Chief Financial Officer
    Nuvilex, Inc.
    Ph: 856-433-6088
    Email: bbarnes@nuvilex.com

    Stephanie Carrington/Amy Glynn
    The Ruth Group
    Ph: 646-536-7017/7023
    Email: scarrington@theruthgroup.com
    Email: aglynn@theruthgroup.com


    Press Contacts:

    Pat Arcand
    Arcand & Madison Public Relations
    Ph: 617-576-7777
    Email: pat@am-pr.com


'/>"/>
SOURCE Nuvilex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nuvilex Gets Update from CK41 on purEffect(TM) Launch Plan
2. Nuvilex Signs Agreement with Jayhur Enterprises to Distribute Infinitink - the Worlds First Permanent, But Easier to Remove Tattoo Ink - in Australia and New Zealand
3. Time Magazine Reports on Infinitink Tattoo Ink From Nuvilex
4. Nuvilex, Inc. Announces Monthly Investor Conference Call
5. Nuvilex Advances Release of Citroxin(TM) Antiviral Surface Cleaner to Help Combat Swine Flu
6. Nuvilex, Inc. Announces Investor Conference Call and Open House
7. Nuvilex, Inc.s Marketing Partner, CK41 to Launch purEffect(TM) in May
8. Nuvilex, Inc. Announces New Pricing for Cinnergen and Launch of dLife Advertising and Promotion Campaign
9. Nuvilex Provides Conference Call Replay Information
10. Nuvilex, Inc. Launches Spring Break Initiatives Designed to Raise Visibility Among Key Demographic Group
11. Nuvilex Infinitink Tattoo Ink Featured on PBS alt.news 26:46 TV Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
Breaking Medicine Technology: